Our blog

Creating Careers: Hitting record-breaking fees across the company
Creating Careers: Hitting record-breaking fees across the company
by Ben Conway
Posted in Pharmaceuticals
November is National Career Development Month, encouraging professionals to celebrate their own career development and focus on their future career choices. To celebrate, we have produced a ‘Creating Careers’ series, in which we interview members of the team about their career development, personal successes, and highlights of their career so far at Invenia Group. In this interview we spoke to Ben Conway – Managing Consultant of our pharmaceutical team. Ben joined Invenia Group as a Recruitment Consultant in August 2020.
Read more
Creating Careers: Manager to divisional director in 4 years
Creating Careers: Manager to divisional director in 4 years
by Christine Sands
Posted in Pharmaceuticals
November is National Career Development Month, encouraging professionals to celebrate their own career development and focus on their future career choices. To celebrate, we have produced a ‘Creating Careers’ series, in which we interview members of the team about their career development, personal successes, and highlights of their career so far at Invenia Group. First up, we interviewed Christine Sands – our Divisional Director of Pharmaceuticals.
Read more
IWD 2022: “It’s all about work-life balance.”
IWD 2022: “It’s all about work-life balance.”
by Christine Sands
Posted in Female Leaders, Pharmaceuticals
For International Women’s Day, we spoke to three of our female senior managers to find out what it is like being a woman in recruitment, how male-dominated the field really is and what we can do to support women to achieve the most senior roles. Our second interview is with Christine Sands who heads up our global pharma team.
Read more
2022: The state of play in the US job market
2022: The state of play in the US job market
by Andrew Maddison
Posted in Job Search, Medical Devices, Pharmaceuticals, Scientific and Process Technology
In this article, we take a look at the state of investment in the market, the size of the talent pool and how this is impacting the job market in the US across the pharma, biotech and medical device industries.
Read more
Addressing the post-Brexit hiring challenges of UK Qualified Persons
Addressing the post-Brexit hiring challenges of UK Qualified Persons
by Christine Sands
Posted in Pharmaceuticals
Before Brexit, the UK could hire QPs from any location within the EU, but now we can only hire QPs based in the UK – resulting in a lack of supply and a rise in day-rates and salaries. We spoke to the Vice President of Quality at a global biotechnology organisation about the challenges of hiring QPs within the UK, and how these might be overcome.
Read more
What life science companies should consider for a US expansion
What life science companies should consider for a US expansion
by James Chippindale
Posted in International Expansion, Medical Devices, Pharmaceuticals, Scientific and Process Technology
Are you a life science company looking to expand into the US? To find out more about what you should consider, we interviewed Joanne Farquharson, President & Chief Executive Officer at Foothold America, a company that helps businesses around the world to expand into the US market.
Read more
CASE STUDY: Generic Pharma Company’s US Expansion
CASE STUDY: Generic Pharma Company’s US Expansion
by Christine Sands
Posted in Case Studies, International Expansion, Pharmaceuticals
An established pharmaceutical company in Europe that develops, manufactures and markets generic medications planned to continue its growth strategy by opening a new subsidiary to target the US generics market. To develop and commercialise a portfolio of generic drugs to market, the company needed a US General Manager.
Read more
Will Covid-19 increase US biosimilar adoption in 2021?
Will Covid-19 increase US biosimilar adoption in 2021?
by Ben Conway
Posted in Pharmaceuticals
In 2019, the US biosimilar market was worth $737.2 million and continues to grow with a CAGR of 46.2% forecast for 2020-2027, however many are frustrated at the current rate of adoption in the US. But with increasing healthcare costs and a growing debt from Covid-19, what does the next year hold for biosimilar adoption across the US?
Read more